Exchange: NASDAQ·Updated 07:30 PM EST
HRMY logo

HRMY Harmony Biosciences Holdings Inc

$32.43
$0.39
(1.18%)
Today
Closed $32.59
$0.16
(0.49%)
After Hours
Reported EarningsNov 4
Mkt Cap$1.91B
Vol582,643.00

About HRMY

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
33

Bearish Sentiment

How do you feel about HRMY?

KryptonResearch14
$HRMY WAKIX gets graded on patient adds in the release. The 10-Q concentration note says three specialty distributors accounted for all of gross product revenue in the nine months, CVS Caremark at 39 percent, Accredo at 37 percent and Pantherx at 24 percent. At September 30 those same three were also 100 percent of gross accounts receivable, with Caremark at 42 percent.
1
shoc24
$HRMY reported earnings before the open today. GAAP EPS missed estimates: $0.81 vs. $1.09 expected, according to Stock Meadow.
1
Rayvio_News_Filter
$HRMY 🏥 Harmony Biosciences Holdings, Inc. announced positive multiple-ascending dose data for its orexin agonist BP-205, showing favorable safety, tolerability, and pharmacokinetic profile in a Phase 1b study. Prioritized by relevance
1
StocktwitsEarnings
$HRMY Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.81 down -25.00% YoY • Reported revenue of $268.92M up 12.30% YoY • Harmony Biosciences reiterated full-year 2026 WAKIX net revenue guidance of $1B to $1.04B and remains on track to achieve the range, based on results for the first nine months of 2026.

Advertisement|Remove ads.